CtrlK
PURR
NASDAQ
Biotechnology
$8.74
USD
+$0.72 (+8.98%)
Last close
Market Cap:
$0
Volume:
33.1M
Previous Close
$8.02
Day Range
$7.80 - $8.79
52 Week Range
$3.01 - $11.62
Average Volume (10 Days)
16.7M
P/E Ratio
0.00
Dividend Yield
0.00%
Hyperliquid Strategies, Inc. is a holding and operating company, which engages in the business of crypto asset management. The company is headquartered in New York City, New York. The company went IPO on 2025-12-03. The firm is focused on accumulating HYPE, the native token of Hyperliquid, a high-performance blockchain custom-built to house all of finance. The Company’s subsidiary is Sonnet BioTherapeutics Holdings, Inc., which is an oncology-focused biotechnology company with a proprietary platform for innovating biologic drugs of single or bifunctional action.
CEO
Mr. David Schamis
Headquaters
New York City, NEW YORK, US
Founded
2025
Employees
0
Hyperliquid Strategies ($PURR) jumps 7% as a NASDAQ proxy for the surging HYPE token. Learn what's driving the rally.
SpaceX will launch at a $1.8 trillion valuation on Nasdaq on Thursday, yet traders on Hyperliquid are pricing the company as high as $2.15 trillion in pre-IPO perpetual contracts.
Explore Hyperliquidâs HYPE and PURR: revenue-backed crypto valued like a stock, P/E growth case, and top staking yields. Click here to read more on the funds.
Bitcoin (CRYPTO: BTC) may not have found its bottom yet, with veteran trader Gareth Soloway warning that the cryptocurrency could still retest $60,000
AKTS
Aktis Oncology Inc
$29.44
-5.5%
ZYME
Zymeworks Inc
$24.15
+1.6%
VRDN
Viridian Therapeutics Inc
$17.90
+2.9%
SRPT
Sarepta Therapeutics Inc
$16.85
+5.2%
